1
Results tagged “PPACA”
What is Happening to Health Care in America?
By Charles Hooper, April 25, 2013
The ACA: A Good Deal? Maybe Not...
By Yevgeniy Feyman, August 27, 2012
To buy insurance or pay the tax? That is the question.
By Ken Hershey, July 13, 2012
Health Insurance Exchanges: Insights into the Resistance
By Rita Numerof, July 13, 2012
Supreme Court Justices Don't Understand America
By Charles Hooper, July 5, 2012
SCOTUS and the Future of Medical Innovation
By Rita Numerof, June 29, 2012
Premium tax in PPACA may substantially distort the health insurance market, undermine competition
By Paul Howard, June 11, 2012
Massive Healthcare Consolidation in the PPACA Era
By Rita Numerof, April 13, 2012
A Two-Year Look Back at PPACA - Why it's Dangerous to Our Health
By Rita Numerof, March 28, 2012
Free Market or Nanny State?
By Rita Numerof, February 17, 2012
The bureaucratic mindset
By Rita Numerof, February 13, 2012
Word of the Year
By Rita Numerof, January 20, 2012
Healthcare Reform... The Job's Not Done
By Rita Numerof, November 22, 2011
Supreme Court could accept PPACA challenge within weeks.
By Paul Howard, October 27, 2011
1
Search
Tags
- $1 (2)
- 000 genome (2)
- 17P (1)
- 2011 (1)
- 2011 approvals (1)
- 2011 drug approvals (1)
- 2012 Cancer Mortality Statistics (1)
- 23andMe (1)
- 3d printing (2)
- 510(k) (2)
- 716 billion (1)
- Aastrom Biosciences (1)
- Abbott (2)
- Abbott Laboratories (1)
- ACA (5)
- aca (10)
- academic medicine (1)
- accelerated approval (9)
- access to care (1)
- accountability (6)
- ACo (1)
- ACO (2)
- ACOs (4)
- Adam Fein (1)
- adaptive licensing (1)
- administrative costs (1)
- Advancing Breakthrough Therapies for Patients Act (1)
- adverse event data (1)
- advisory committee (3)
- aei (1)
- AEI (2)
- Aetna (1)
- Affodable Care Act (1)
- Affordable Care Act (15)
- affordable care act (2)
- Agouron (1)
- AIDS (6)
- Aids Drug Assistance Programs (1)
- Akiro Endo (1)
- Alex (1)
- Alex Tabarrok (4)
- alextabarrok (2)
- ama (1)
- american action forum (2)
- American Action Forum (6)
- American Action Network (1)
- American Bankers Association (1)
- American Cancer Society (1)
- American Medical Association (1)
- American Society of Health-System Pharmacists (1)
- AmerisourceBergen (1)
- Amy Klobuchar (1)
- Andrew Jack (1)
- angel activity (1)
- anti-NGF (1)
- Antibacterial (2)
- antibiotic drug development (1)
- antibiotic drug resistance (2)
- antibiotic drug resisteance (1)
- antibiotics (3)
- antivirals (1)
- Anupam Jena (1)
- appropriations act (1)
- argus II (1)
- arthritis (1)
- asco (1)
- ASCO (4)
- ASOs (1)
- Associated Press (1)
- AstraZeneca (3)
- Atlas Venture (1)
- Atripla (1)
- Aurora Health Care (1)
- autism (1)
- autodesk (1)
- autoimmune disorders (1)
- autologous stem cells (1)
- Avado (1)
- Avastin (8)
- avik roy (1)
- Avik Roy (8)
- AZT (1)
- balanced budget (1)
- Barack Obama (4)
- barbiturates (1)
- Baumol's disease (1)
- Bayer (3)
- Bayou Health (1)
- bea (1)
- Beauty (1)
- Berkley Wellness Newsletter (1)
- Berlin (1)
- Best Doctors (2)
- Best Pharmaceuticals for Children Act (BPCA) (1)
- beta-blockers (2)
- Beth Israel (1)
- bias (1)
- Bias in high-tier medical jouranls (1)
- biden (2)
- big data (3)
- Bill Gates (1)
- billions (1)
- BioCentury (4)
- Biomarker (1)
- Biomarkers (1)
- biomarkers (1)
- Biosimilars User Fee Act (1)
- biotech (4)
- biotechnology (1)
- Biotechnology (2)
- Biotechnology and Pharmaceuticals (1)
- birth control (1)
- Blahous (2)
- blindness (1)
- block grant (1)
- block grants (1)
- blockbuster (3)
- Bloomberg (1)
- boceprevir (1)
- bodega clinicas (1)
- Boehringer Ingelheim (1)
- Booth (1)
- boston (1)
- Boston (1)
- brad delong (1)
- BRCA (1)
- breakthrough breast cancer therapies (1)
- breakthrough therapies (3)
- Breast (1)
- Breast cancer (1)
- breast cancer (8)
- Bristol-Myers Squibb (4)
- Bruce Booth (3)
- bruce booth (1)
- bryan quinn (1)
- budget (2)
- bundled payments (1)
- Burill Report (1)
- Burroughs Wellcome (1)
- Business (7)
- buy in (1)
- calendar days (1)
- california (1)
- California (1)
- California Healthcare Institute (1)
- CAM-1 (1)
- cancer (8)
- Cancer (3)
- cancer clinical trials (1)
- cancer drug shortages (2)
- cancer genomics (2)
- cancer immunotherapy (1)
- cancer vaccines (1)
- capital (1)
- capitation (1)
- cardiovascular disease (2)
- Caremark (1)
- catastrophic care (1)
- Catastrophic Care (1)
- Caveat emptor (1)
- cbo (3)
- CBO (2)
- CBO demonstration projects (1)
- CDC (1)
- cdhp (1)
- CDRH (1)
- celltex (1)
- center for economic and policy research (1)
- CEO survey (1)
- Charles Hooper (1)
- Cheesecake Factory (1)
- childhood vaccinations (1)
- China (3)
- choice and competition (1)
- Chris Conover (1)
- Chris Van Hollen (1)
- City Journal (4)
- CLASS (1)
- CLASS Act (3)
- Clinical trial (4)
- clinical trials (5)
- clinicaltrial (1)
- Clinton (1)
- cms (1)
- CMS (4)
- CNN (1)
- Cochrane Collaboration (1)
- Coleen Klasmeier (1)
- collistin (1)
- Cologne (1)
- Colorectal cancer (1)
- Commissioner Margaret Hamburg (1)
- common benefits (1)
- commonwealth fund (1)
- communication (1)
- companion diagnostics (1)
- Comparative effectiveness research (3)
- compassionate use (1)
- competition (1)
- competitive bidding (2)
- compliance (3)
- compulsory licensing (1)
- conditional approval (2)
- Conditions and Diseases (1)
- conference committee (1)
- conflict of interest (2)
- Conflict of interest regulations (1)
- conflict of interest rules (1)
- conflicts of interest (1)
- Congress (11)
- Congressional Budget Office (1)
- Congressional testimony (1)
- connecticut (1)
- consolidation (2)
- Constitution (3)
- consumer (1)
- Consumer (1)
- consumer advocates (1)
- consumer driven health care (3)
- Consumer Reports (2)
- consumer reports (1)
- consumer surplus (1)
- contraceptives (1)
- corporate espionage (1)
- Corporate tax reform (1)
- cost (3)
- costs (2)
- costs of drug development (1)
- Coventry Health Care (1)
- Craig Venter (1)
- Creative Destruction of Medicine (1)
- Crestor (1)
- Crime (1)
- cures (1)
- cuts (1)
- cutting costs (1)
- cystic fibrosis (2)
- daclatasvir (1)
- Daniel Klein (1)
- datamining for helath care (1)
- David Cameron (1)
- David Chase (1)
- David Gamage (1)
- David Goldhill (1)
- David Gratzer (1)
- David Rothman (1)
- David Shlaes (2)
- Dean Baker (1)
- debate (1)
- debates (1)
- debt service (1)
- decentralized information (1)
- deficit (1)
- Deficit (1)
- deficit reduction (1)
- deficit reform (1)
- defined contribution (1)
- Delalutin (1)
- Democratic National Convention (1)
- Department of Health and Human Services v. Florida (1)
- Department of Justice (1)
- Derek Lowe (8)
- Deval Patrick (1)
- Developing country (1)
- development (1)
- diabetes (2)
- diabetes pill (1)
- Diagnostic test (2)
- diagnostics (3)
- Diana Furchtgott-Roth (2)
- diet pill (1)
- direct primary care (3)
- direct to consumer advertising (1)
- disease (1)
- disruptive innovation (3)
- disruptive innovations (1)
- doc fix (1)
- doctor salaries (1)
- doctor-patient relationship (1)
- doctors object to Obamacare (1)
- Donald Berwick (1)
- donut hole (1)
- Douglas Holtz-Eakin (7)
- Doxil (1)
- Dr. Andrew von Eschenbach (2)
- Dr. Janet Woodcock (1)
- Dr. Peter Agus (1)
- Drug and Device Law Blog (1)
- drug approval (1)
- Drug Channels (2)
- drug costs (1)
- drug development (6)
- Drug development (2)
- drug importation (2)
- drug price controls (1)
- drug prices (2)
- drug reps (1)
- drug shortage (2)
- drug shortages (6)
- Drug shortages (1)
- drug trials (1)
- dsh (1)
- dual eligibles (2)
- Duchenne muscular dystrophy (1)
- E.J. McMahon (1)
- economic outlook (1)
- Economic Value of Medical Research (1)
- Economics (2)
- Ed Silverman (1)
- efficacy (3)
- electronic health records (1)
- eligibility age (1)
- EMA (2)
- emergence (1)
- Emma Whitehead (1)
- Empire Center (2)
- employer deduction for health insurance (1)
- employer loophole (1)
- employer-based coverage (1)
- employment (1)
- Energy and Commerce (1)
- epidemic (1)
- Erbitux (1)
- Eric Topol (1)
- Erik Paulsen (1)
- ESPN (1)
- essential health benefits (1)
- eteplirsen (1)
- European Union (1)
- evidence (1)
- exchange program (1)
- exchanges (1)
- expanded access (1)
- expansion (1)
- expenditures (1)
- F-150 (1)
- Fact Checker (1)
- fact-check (1)
- fake Avastin (1)
- Families USA (1)
- fda (8)
- FDA (96)
- FDA email surveillance (1)
- FDA Personalized medicine (1)
- fda reform (6)
- FDA reform (4)
- FDA Voice (1)
- FDAMA (1)
- federal appeals court (1)
- federal budget deficit (1)
- federal exchange (1)
- Fen-Phen (1)
- financial conflicts of interest (1)
- Financial Times (1)
- First Amendment to the United States Constitution (2)
- first time funding (1)
- fiscal cliff (3)
- fiscal problems (1)
- FJ Cruiser (1)
- flexibility (1)
- Flu (1)
- Food & Drug Administration (1)
- Food and Drug Administration (11)
- Forbes (6)
- Ford (1)
- France (1)
- Francis Collins (1)
- fraud and abuse (2)
- Frederic Bastiat (1)
- Frederick Banting (1)
- free rider (1)
- free speech (1)
- freedom (1)
- Friedrich Hayek (2)
- Friends of Cancer Research (1)
- ftc (1)
- GAIN Act (1)
- gain act (1)
- galapagos (1)
- Galen (1)
- gao (3)
- GAO (1)
- Gardasil (1)
- Gates Foundation (1)
- Gawande (1)
- Geisinger (1)
- gene sequencing (1)
- Genentech (1)
- generic (1)
- generic drug shortages (4)
- generic drug user fee program (1)
- generic drugs (3)
- Genomic Law Report (1)
- genomic medicine (1)
- genomics (2)
- Germany (1)
- Gilead Sciences (3)
- Gina Kolata (1)
- GlaxoSmithKline (5)
- Gleevec (1)
- Glenn Reynolds (1)
- Glimcher (1)
- Glivec (1)
- global health care budgets (1)
- global pharmaceutical industry (1)
- GNS Healthcare (1)
- Government (1)
- government health care programs (1)
- Governor Jindal (1)
- GPOs (2)
- grand bargain (1)
- gray market (1)
- Greg Conko (1)
- GSA (1)
- GSK (1)
- H.R. 5651 (1)
- Hamburg (3)
- Happy Holidays (1)
- hard truths for health care reform (1)
- hatch waxman (1)
- Hayek (1)
- hdhp (1)
- Health (6)
- Health care (1)
- health care (2)
- health care costs (4)
- Health care reform (1)
- health care reform (6)
- health exchanges (1)
- health insurance (1)
- health insurance exchanges (2)
- health insurance premiums (1)
- health IT (1)
- Health maintenance organization (1)
- health outcomes (1)
- health savings accounts (1)
- Health Savings Accounts (1)
- healthcare (1)
- Healthcare at a Turning Point (1)
- healthcare cost (1)
- healthcare costs (2)
- healthcare reform (4)
- healthcare spending (3)
- Healthcare Spending (2)
- heart disease (1)
- Hepatitis C (2)
- hepatitis C (1)
- Herceptin (1)
- HHS (3)
- high risk pools (1)
- higher costs (1)
- Hippocratic Oath (1)
- HIV (4)
- HIX (1)
- home health care (1)
- Honda Ridgeline (1)
- Hormone replacement therapy (1)
- hospitals (1)
- House (1)
- house budget (1)
- House Committee on Government Oversight (1)
- hsa (3)
- HSA Council (1)
- http://media.manhattan-institute.org/podcasts/091412_Howard_Holtz-Eakin_mpt.mp3 (1)
- http://washingtonexaminer.com/manhattan-moment-obamacare-may-be-constitutional-but-it-is-bad-policy/article/2500932 (1)
- Illumina (1)
- immunotherapy (1)
- impact (1)
- impacts (1)
- In the Pipeline (4)
- Incivek (1)
- Independent Payment Advisory Board (1)
- India (4)
- individual mandate (7)
- industry consolidation (1)
- influenza research (1)
- innnovation (1)
- innovation (15)
- Innovation (2)
- Instapundit (1)
- Institute of Medicine (2)
- insurance (8)
- insurance costs (1)
- insurers (1)
- Intellectual property (1)
- intellectual property rights (1)
- intelligence squared (1)
- interest rate (1)
- interim report (1)
- investments (2)
- investors (1)
- IP protection (1)
- IPAB (2)
- iPhone (1)
- iPod (1)
- irobot (1)
- Jack Scannell (1)
- jama (1)
- James Capretta (1)
- James Pinkerton (3)
- Jesus (1)
- Jim Copland (1)
- Jim Gerlach (1)
- job creation (1)
- job cuts (1)
- job lock (1)
- Jobs Council (2)
- Joe Nocera (1)
- Joel White (1)
- John LaMattina (1)
- Jon Entine (1)
- Jonathan Chait (1)
- jonathan cohn (1)
- jonathan gruber (1)
- Josh Archambault (1)
- Josh Barro (1)
- Josh Bloom (2)
- Joshua Archambault (1)
- Journal of the American Medical Association (1)
- Justice Department (1)
- kaiser (1)
- Kaiser (2)
- Kaiser Health News (1)
- Kalydeco (1)
- Ketek (1)
- khn (1)
- kidney cancer (1)
- kinase inhibitors (1)
- Kleiner Perkins Caufield & Byers (1)
- knee replacements (1)
- Knowledge (1)
- krugman (1)
- KV Pharmaceutical (3)
- L.A. Times (2)
- labor (1)
- labor costs (1)
- Lawrence Tribe (1)
- Leavitt Partners (1)
- liberty (1)
- life expectancy (1)
- LigoCyte (1)
- Lipitor (4)
- Liptruzet (1)
- long term care program (1)
- Lorqess (1)
- Los Angeles Times (1)
- Louisiana (1)
- Luke Timmerman (3)
- MabThera (1)
- macular degeneration (1)
- Magic Johnson (1)
- Makary (1)
- Makena (3)
- malaria (1)
- Manhattan Institute (2)
- manufacturing (2)
- Marcia Angell (2)
- Margaret Hamburg (2)
- Mark McClellan (1)
- Mark Mills (1)
- Market capitalization (1)
- market-based (1)
- marriage penalty (1)
- Massachusetts (2)
- matt yglesias (1)
- Matthew Herper (1)
- Matthew Yglesias (2)
- Maurice Hilleman (2)
- mayo clinic (1)
- MD Anderson (1)
- MDUFA (3)
- medicaid (9)
- Medicaid (5)
- Medicaid expansion (2)
- Medicaid fraud (1)
- medicaid rebate (1)
- medicaid spending (1)
- medical device (3)
- Medical device (3)
- medical innovation (1)
- medical-industrial complex (1)
- medicare (17)
- Medicare (12)
- medicare and medicaid (1)
- medicare part d (3)
- Medicare Part D (5)
- Medicare reform (3)
- medicare reform (2)
- Medication and Drugs (1)
- medicine (1)
- mediscare (1)
- Medscape (1)
- Megan McArdle (2)
- MelaFind (1)
- meningitis vaccine (1)
- Menopause (1)
- Mercatus Center (2)
- mercer (1)
- Merck (7)
- Merck & Co. (1)
- Merck & Co. (3)
- mergers (1)
- methotrexate (1)
- MGMA (1)
- Michael Bennet (2)
- Michael Mandel (1)
- Michelle Malkin (1)
- military deaths (1)
- Milken Institute (1)
- mini-med (1)
- minimum essential coverage (1)
- Mitt Romney (1)
- mitt romney (1)
- mlr (1)
- MLR (1)
- mobile apps (1)
- MODDERN Cures (1)
- MODDERN Cures Act (1)
- Moffit Cancer Center (1)
- Moore's Law (1)
- MPT (1)
- MRSA (1)
- multiple myeloma (1)
- Myriad Genetics (1)
- Namibia (1)
- National Affairs (1)
- National Breast Cancer Awareness Month (1)
- National Cancer Institute (1)
- national commission on physician payment reform (1)
- National Health Council (1)
- National health expenditures (1)
- national healthcare expenditures (1)
- National Institutes of Health (4)
- National Journal (1)
- National Review (2)
- National Venture Capital Association (3)
- Nature Biotechnology (1)
- Nature Reviews Drug Discovery (1)
- nausea (1)
- NBER (1)
- NCATs (1)
- neglected diseases (1)
- NEJM (1)
- net present value (1)
- Neuroendocrine tumor (1)
- New Drug Application (1)
- New York (2)
- New York Department of Health (1)
- New York Post (1)
- New York Times (11)
- Nexavar (2)
- nhe (1)
- NICE (1)
- Nicole Gelinas (1)
- nih (1)
- NIH (3)
- norovirus (1)
- Novartis (2)
- Novo Nordisk (1)
- npr (1)
- NPR (2)
- obama (2)
- Obama (5)
- Obama Administration (1)
- obamacare (13)
- Obamacare (22)
- obamacare cost (2)
- obamacare evaluation project (1)
- obamacare expansion (1)
- obesity (4)
- ODD (1)
- oecd (2)
- OECD (5)
- off label use (2)
- off-label prescribing (1)
- off-label promotion (4)
- omb (1)
- omega-3 fish oil pills (1)
- oncology (1)
- Onyx (2)
- opt-out (1)
- optum labs (1)
- Oracle (1)
- organovo (1)
- Orphan drug (1)
- orphan drugs (8)
- OTC (1)
- out of pocket (1)
- outcomes (4)
- Over the counter (1)
- pain (2)
- pain medicine (1)
- Pancreatic cancer (1)
- papa johns (1)
- paradigm (2)
- parallel review (1)
- Parallel Review (1)
- Parkinson's disease (2)
- Parkinson's Disease (1)
- part-time (1)
- patent (5)
- Patent (2)
- patents (3)
- Patient (1)
- Patient Access to Medical Innovation Act (1)
- Patient Protection and Affordable Care Act (13)
- patient welfare (1)
- Patient's FDA (1)
- PATIENTS (1)
- PATIENTS' FDA Act (1)
- Paul (1)
- Paul Graham (1)
- Paul Howard (1)
- Paul Krugman (1)
- Paul Offit (1)
- Paul Ryan (5)
- pay for delay (1)
- pay for peformance (1)
- payment reform (2)
- pdufa (1)
- PDUFA (10)
- PDUFA V (2)
- Pediatric Research Equity Act (PREA) (1)
- Percentage (1)
- performance (1)
- persistence (1)
- Personalized medicine (1)
- personalized medicine (11)
- peter huber (1)
- Peter Huber (2)
- Peter Pitts (1)
- Peter Suderman (6)
- Peter Thiel (1)
- Peyton Manning (1)
- pfizer (1)
- Pfizer (8)
- pharmaceutical advertising (1)
- Pharmaceutical drug (1)
- pharmaceutical industry (7)
- Pharmaceutical industry (8)
- pharmaceuticals (1)
- Pharmaceuticals (1)
- pharmacoeconomics (1)
- Pharmalot (2)
- philosophical exemption (1)
- PhRMA (1)
- Physician (1)
- physician shortage (1)
- physicians (1)
- pilot projects (1)
- Pioneer Institute (2)
- placebo effect (2)
- Plan B (1)
- Point of Law (1)
- Politico (2)
- Ponzi Scheme (1)
- post-market surveillance (1)
- PPACA (14)
- pre-IND meetings (1)
- pre-term birth (1)
- Precision Medicine (1)
- premium support (3)
- premium tax (1)
- Prescription drug (2)
- Prescription Drug User Fee Act (3)
- President (1)
- President Obama (5)
- preventative care (1)
- price controls (3)
- Price Controls (1)
- pricing (3)
- primary care (2)
- Princeton University (1)
- private insurance (1)
- productivity (1)
- Products Evaluation (1)
- Progressive Policy Institute (1)
- Project FDA (1)
- prostate cancer (2)
- proteomics (1)
- PSA (2)
- public good (1)
- Qnexa (2)
- Qsymia (2)
- R&D (1)
- r&d (1)
- R&D (4)
- RAND (1)
- rand (1)
- rare side effects (1)
- rationing (1)
- rbrvs (1)
- Reagan Udall (2)
- Real Clear Markets (1)
- Real world evidence (1)
- RealClearMarkets (1)
- Reason (4)
- recess appointment (1)
- reform (2)
- Regenerative Sciences (1)
- Regeneron (1)
- regulation (10)
- regulations (1)
- regulatory risk (1)
- regulatory uncertainty (1)
- Reihan Salam (1)
- religion (1)
- REMS (1)
- Representative Paul Ryan (1)
- Republican Party (1)
- research and development (1)
- research hubs (1)
- resistance (1)
- resistant bacteria (1)
- retail clinics (2)
- Reuters (1)
- revenues (1)
- rhetoric and realities update (1)
- Richard Burr (1)
- Richard Epstein (2)
- Richard Nathan (1)
- Rita Numerof (1)
- Rituxan (1)
- Robert Book (1)
- Robert Samuelson (1)
- Roche (4)
- Rofecoxib (1)
- Roll Call (1)
- Roman Lesko (1)
- Romney (2)
- romney-ryan (4)
- Ron Paul (1)
- Ron Wyden (2)
- Ronald Perelman (1)
- Ronald Reagan (1)
- Roy Ramthun (1)
- rpvita (1)
- Russell Sykes (1)
- ryan (2)
- Ryan (1)
- S. 3187 (1)
- SA 890 (1)
- safety (6)
- Samuel Scott (1)
- Sanofi (1)
- Sarepta Therapeutics (1)
- science policy (1)
- scott gottlieb (1)
- Scott Gottlieb (5)
- SCOTUS (2)
- Secretary Sebelius (1)
- Section 273 (1)
- segmented (1)
- Senate Finance Committee (1)
- Senator Al Franken (1)
- Senator Bennet (1)
- Senator Burr (4)
- Senator Claire McCaskill (1)
- Senator Coburn (3)
- Senator Hatch (2)
- Senator Kay Hagan (1)
- Senator Lamar Alexander (1)
- Senator Richard Durbin (1)
- Senator Ron Wyden (1)
- sgr (2)
- SGR (1)
- Sidney Wolfe (1)
- Siga (1)
- Siga Technologies (1)
- Silicon Valley (1)
- simpson-bowles (2)
- Singapore (1)
- small pox (1)
- snake oil sales (1)
- society of actuaries (1)
- soda (1)
- solohealth (1)
- Solyndra (1)
- sorafenib (1)
- SOTU (1)
- Soviet Union (1)
- specialists (1)
- spending problem (1)
- SSRI (1)
- Stanford (1)
- Startup company (2)
- state finances (1)
- state health insurance exchanges (2)
- state insurance exchanges (1)
- state of the union (2)
- states (3)
- statins (1)
- Statistical significance (3)
- Statistics (1)
- stem cells (5)
- Stephen Parente (2)
- Steve Jobs (2)
- Steve Usdin (1)
- sticker shock (2)
- Stifling New Cures (1)
- stomach flu (1)
- subsidies (1)
- Super Committee (2)
- supplements (1)
- Supreme Court (11)
- Surpreme Court (1)
- Susan G Komen (1)
- Susan G. Komen for the Cure (1)
- Sustainable Growth Rate (2)
- Syntex Labs (1)
- Tamiflu (1)
- Tara Parker-Pope (1)
- targeted cancer drugs (1)
- tax foundation (1)
- tax policy (2)
- taxes (4)
- Ted Frank (1)
- telaprevir (1)
- Teledoc (1)
- telemedicine (3)
- Test data exclusivity (1)
- thalidomide (2)
- The End of Illness (1)
- The Great Experiment (1)
- The Perfect Storm (1)
- The Scientist (1)
- The Torch (1)
- Thomas P. Stossel (2)
- Thomas Scully (2)
- Thrombus (1)
- Tibotec (1)
- Tokyo Game Show (1)
- Tomas Philipson (1)
- Toyota (1)
- Toyota 4Runner (1)
- Toyota FJ Cruiser (1)
- track-and-trace (1)
- translational research (1)
- transparency (4)
- Travel and Tourism (1)
- TREAT (1)
- tricorder (1)
- Truvada (1)
- Tufts Center for the Study of Drug Development (1)
- Tufts University (1)
- Tygacil (1)
- U.K. (1)
- U.S. Food and Drug Administration (1)
- U.S. government research (1)
- U.S. medical innovation (1)
- U.S. Preventive Services Task Force (1)
- U.S. Senate testimony (1)
- uninsured (2)
- united health (1)
- united health group (1)
- United Health Group (1)
- United State (1)
- united states (1)
- United States (6)
- United States Congress (2)
- United States House Committee on Energy and Commerce (1)
- United States v. Caronia (2)
- universal flu vaccine (1)
- University of California San Francisco (1)
- update (1)
- upper payment limit (1)
- urban institute (2)
- USA Today (1)
- user fee (2)
- user fee agreements (1)
- utah (1)
- Uwe Reinhardt (1)
- vaccination (1)
- vaccine (4)
- Vehicle (1)
- Venture capital (4)
- venture capital (3)
- Vertex (2)
- Vertex Pharmaceuticals (3)
- Via Meadia (1)
- Vic Wood (1)
- vice president (2)
- Victoria Cross (2)
- Victrelis (1)
- Vioxx (4)
- virtual clinical trials (1)
- Vivus (2)
- Vytorin (1)
- waiting times (2)
- wal-mart (1)
- Wal-Mart (1)
- Wall Street Journal (8)
- Wall Street Journal HIV (1)
- walmart (1)
- Washington (1)
- Washington Examiner (1)
- Washington Post (2)
- Washington State (1)
- weight loss (1)
- Weill Cornell Medical College of Cornell University (1)
- welfare reform (1)
- Wellness Letter (1)
- whistleblower (1)
- White House (1)
- wholesalers (1)
- whooping cough (1)
- Wolf Blitzer (1)
- Wyden (1)
- Wyden-Ryan (2)
- Xalkori (1)
- xconomy (1)
- Xconomy (7)
- Zofran (1)
keep in touch     |
Tag Cloud
Archives
